4743 Stock Overview
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oneness Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$105.00 |
| 52 Week High | NT$200.96 |
| 52 Week Low | NT$101.00 |
| Beta | 1.55 |
| 11 Month Change | -24.46% |
| 3 Month Change | -33.75% |
| 1 Year Change | -45.96% |
| 33 Year Change | -57.91% |
| 5 Year Change | 335.53% |
| Change since IPO | 728.17% |
Recent News & Updates
Shareholder Returns
| 4743 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.4% | 0.6% | -0.8% |
| 1Y | -46.0% | 9.2% | 29.0% |
Return vs Industry: 4743 underperformed the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 4743 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 4743 volatility | |
|---|---|
| 4743 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4743 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4743's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Shuling Cheng | www.onenessbio.com |
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.
Oneness Biotech Co., Ltd. Fundamentals Summary
| 4743 fundamental statistics | |
|---|---|
| Market cap | NT$50.13b |
| Earnings (TTM) | -NT$1.26b |
| Revenue (TTM) | NT$112.20m |
446.8x
P/S Ratio-39.8x
P/E RatioIs 4743 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4743 income statement (TTM) | |
|---|---|
| Revenue | NT$112.20m |
| Cost of Revenue | NT$49.12m |
| Gross Profit | NT$63.08m |
| Other Expenses | NT$1.32b |
| Earnings | -NT$1.26b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 56.22% |
| Net Profit Margin | -1,121.83% |
| Debt/Equity Ratio | 0% |
How did 4743 perform over the long term?
See historical performance and comparison